false 0001821586 0001821586 2024-12-12 2024-12-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 or 15(d) of the

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): December 12, 2024

 

MOONLAKE IMMUNOTHERAPEUTICS

(Exact Name of Registrant as Specified in Its Charter)

 

Cayman Islands   001-39630   98-1711963
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

Dorfstrasse 29

6300 Zug

Switzerland

(Address of Principal Executive Offices and Zip Code)

 

41 415108022

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A ordinary share, par value $0.0001 per share  

MLTX

   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).        

 

Emerging growth company        ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.        ☐

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Director Departure

 

On December 12, 2024, Dr. Kara Lassen notified the board of directors (the “Board”) of MoonLake Immunotherapeutics (the “Company”) of her intent to resign as a member of the Board, effective as of December 31, 2024 (the “Effective Date”), due to the increased responsibilities of her new role at Roche Pharma Research & Early Development. As of the Effective Date, the size of the Board will be reduced from seven to six directors. Dr. Lassen’s decision to resign from the Board was not the result of any dispute or disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company and the Board extend their deepest gratitude to Dr. Lassen for her contributions to the Company.

 

Approval of Long-Term Incentive Program

 

The Board also approved a long-term incentive program consisting of an annual equity grant to certain employees in the form of either restricted stock awards or stock options, depending on the employee’s election. As part of that program, in January 2025, Dr. Jorge Santos da Silva, the Chief Executive Officer, Dr. Kristian Reich, the Chief Scientific Officer, and Matthias Bodenstedt, the Chief Financial Officer, are each expected to receive an equity grant with a grant date fair value of $4 million, to vest over four years.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MOONLAKE IMMUNOTHERAPEUTICS
 
Date: December 18, 2024 By: /s/ Matthias Bodenstedt
  Name: Matthias Bodenstedt
  Title: Chief Financial Officer

 

 

2

 

 

v3.24.4
Cover
Dec. 12, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 12, 2024
Entity File Number 001-39630
Entity Registrant Name MOONLAKE IMMUNOTHERAPEUTICS
Entity Central Index Key 0001821586
Entity Tax Identification Number 98-1711963
Entity Incorporation, State or Country Code E9
Entity Address, Address Line One Dorfstrasse 29
Entity Address, City or Town Zug
Entity Address, Country CH
Entity Address, Postal Zip Code 6300
City Area Code 41
Local Phone Number 415108022
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A ordinary share, par value $0.0001 per share
Trading Symbol MLTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Grafico Azioni MoonLake Immunotherapeut... (NASDAQ:MLTX)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di MoonLake Immunotherapeut...
Grafico Azioni MoonLake Immunotherapeut... (NASDAQ:MLTX)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di MoonLake Immunotherapeut...